Novavax Inc
NASDAQ:NVAX

Watchlist Manager
Novavax Inc Logo
Novavax Inc
NASDAQ:NVAX
Watchlist
Price: 8.845 USD -5.1%
Market Cap: 1.4B USD
Have any thoughts about
Novavax Inc?
Write Note

Novavax Inc
Other Non-Cash Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Novavax Inc
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
Novavax Inc
NASDAQ:NVAX
Other Non-Cash Items
$99.7m
CAGR 3-Years
-28%
CAGR 5-Years
57%
CAGR 10-Years
36%
Abbvie Inc
NYSE:ABBV
Other Non-Cash Items
$7B
CAGR 3-Years
-10%
CAGR 5-Years
-6%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Other Non-Cash Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Other Non-Cash Items
-$419m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Non-Cash Items
$742.4m
CAGR 3-Years
37%
CAGR 5-Years
13%
CAGR 10-Years
4%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Non-Cash Items
$480.1m
CAGR 3-Years
24%
CAGR 5-Years
-6%
CAGR 10-Years
4%
No Stocks Found

Novavax Inc
Glance View

Market Cap
1.4B USD
Industry
Biotechnology

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 1,541 full-time employees. The firm promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).

NVAX Intrinsic Value
7.401 USD
Overvaluation 16%
Intrinsic Value
Price

See Also

What is Novavax Inc's Other Non-Cash Items?
Other Non-Cash Items
99.7m USD

Based on the financial report for Sep 30, 2024, Novavax Inc's Other Non-Cash Items amounts to 99.7m USD.

What is Novavax Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 10Y
36%

Over the last year, the Other Non-Cash Items growth was -56%. The average annual Other Non-Cash Items growth rates for Novavax Inc have been -28% over the past three years , 57% over the past five years , and 36% over the past ten years .

Back to Top